|
Synonyms: compound 352 [WO2023141432] | MXE-829 | MXE829 | MZE829
Compound class:
Synthetic organic
Comment: Alcedaplin (MXE829) is an apolipoprotein L1 (APOL1) inhibitor/modulator that is proposed to treat APOL1-associated nephropathy, particularly in individuals with a high-risk APOL1 genotype [1]. It is designed to inhibit both APOL1 pore formation and channel function.
|
|
|||||||||||||||||||||||||||||||||||
| No information available. |
Summary of Clinical Use ![]() |
| MZE829/MXE829 was progressed as a clinical candidate. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT06830629 | A Phase 2 Study of MZE829 in Adults With APOL1 Kidney Disease | Phase 2 Interventional | Maze Therapeutics | ||